The efficacy and mechanism action of rvcsd, a new herbal agent, on immune suppression and cartilage protection in a mouse model of rheumatoid arthritis

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 211-221

  Lee, Jae Dong ^a   Huh, Jeong Eun ^a   Baek, Yong Hyeon ^b   Cho, Ku Chil ^a   Choi, Do Young ^a   Park, Dong Suk ^b  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Anti inflammation; Cartilage protection; Collagen induced arthritis; Immune suppression; RvCSd (oriental herbal mixture)

Indexed keywords

CINNAMOMUM CASSIA EXTRACT PLUS RHUS VERNICIFLUA EXTRACT PLUS SAPOSHNIKOVIA DIVARICATA EXTRACT; COLLAGEN TYPE 2; GAMMA INTERFERON; HERBACEOUS AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; METHOTREXATE; PLANT EXTRACT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CINNAMOMUM CASSIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME REGULATION; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; JOINT SWELLING; MALE; MOUSE; NONHUMAN; ORIENTAL MEDICINE; POISON IVY; RAT; RHEUMATOID ARTHRITIS; RHUS VERNICIFLUA; SAPOSHNIKOVIA DIVARICATA; SYNOVITIS; ANIMAL; ARTHRITIS; CARTILAGE; DBA MOUSE; DRUG EFFECT; SPRAGUE DAWLEY RAT;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CARTILAGE; DRUGS, CHINESE HERBAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED DBA; RATS; RATS, SPRAGUE-DAWLEY; SYNOVITIS;

EID: 65449150930     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08256FP     Document Type: Article

References (48)

1. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 1998;41:951-962.
2. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307-310.
3. Garnero P, Geusens P, Landewe R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:S54-S58.
4. Garnero P, Rousseau J-C, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 2000;43:953-968.
5. Cunnane G, FitzGerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metallo- proteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum. 2001;44:2263-2274.
6. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metallo- proteinases and tissue inhibitors of metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol. 2004;31:238-242.
7. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases in rheumatoid arthritis is T cell dependent. Clin Immunol. 1999;90:65-78.
8. Matrisian L. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
9. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 2000;12:195-199.
10. Burger D, Rezzonico R, Li JM, Modoux C, Pierce RA, Welgus HG, et al. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum. 1998;41: 1748-1759.
11. Begley CG, Nicola NA. Resolving conflicting signals: cross inhibition of cytokine signaling pathways. Blood. 1999;93: 1443-1447.
12. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology. 2005;12:183-189.
13. Williams RO, Whyte A, Waldmann H. Resistance to collagen induced arthritis in DBA /1 mice by intraperitoneal administration of soluble type II collagen involves both CD4+ and CD8+ T lymphocytes. Autoimmunity. 1989;4:237-245.
14. Romagnani P, Annunziato F, Piccinni MP, Maggi E, Romagnani S. Th1 /Th2 cells, their associated molecules and role in pathophysiology. Eur Cytokine Netw. 2000;11:510-511.
15. Kidd P. Th1 /Th2 balance: the hypothesis, its limitation and implications for health and disease. Altern Med Rev. 2003;8: 223-246.
16. Fung HB, Kirschenbaum HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin Ther. 1999;21: 1131-1157.
17. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
18. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167-2179.
19. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473-488.
20. Huh J. Dong Ui Bo Gam [The precious mirror of oriental medicine]. Seoul: Namsangdang; 1999. (in Korean)
21. Kim HC. Herbalogy. Seoul: Young Lim Sa; 2000.
22. Lee HJ. Bone Cho Kang Mook [compendium of material medica]. Seoul: Yeoil; 2007. (in Korean)
23. Seo UK, Lee YJ, Kim JK, Cha BY, Kim DW, Nam KS, et al. Large-scale and effective screening of Korean medicinal plants for inhibitory activity on matrix metalloproteinase-9. J Ethnopharmacol. 2005;97:101-106. (Pubitemid 40094535)
24. Kuo YC, Lin YL, Huang CP, Shu JW, Tsai WJ. A tumor cell growth inhibitor from Saposhnikovae divaricata. Cancer Invest. 2002;20:955-964.
25. Jung CH, Jun CY, Lee S, Park CH, Cho K, Ko SG. Rhus verniciflua stokes extract: radical scavenging activities and protective effects on H2O2-induced cytotoxicity in macrophage RAW 264.7 cell lines. Biol Pharm Bull. 2006;29:1603-1607.
26. Kim JH, Kim HP, Jung CH, Hong MH, Hong MC, Bae HS, et al. Inhibition of cell cycle progression via p27Kip1 upregulation and apoptosis induction by an ethanol extract of Rhus verniciflua Stokes in AGS gastric cancer cells. Int J Mol Med. 2006;18:201-208.
27. Lee SH, Seo GS, Sohn DH. Inhibition of lipopolysaccharide- induced expression of inducible nitric oxide synthase by butein in RAW 264.7 cells. Biochem Biophys Res Commun. 2004; 323:125-132.
28. Kim JB. Identification of antioxidative component from stem bark of Rhus verniciflua. Korean J Food Nutr. 2003;16:60-65.
29. Lee JC, Lim KT, Jang YS. Identification of Rhus verniciflua Stokes compounds that exhibit free radical scavenging and anti- apoptotic properties. Biochim Biophys Acta. 2002;1570:181-191.
30. Son YO, Lee KY, Lee JC, Jang HS, Kim JC, Jeon YM, et al. Selective antiproliferative and apoptotic effects of flavonoids purified from Rhus verniciflua Stokes on normal versus transformed hepatic cell lines. Toxicol Lett. 2005;155:115-125. (Pubitemid 39600743)
31. Lim KT, Hu C, Kitts DD. Antioxidant activity of a Rhus verniciflua Stokes ethanol extract. Food Chem Toxicol. 2001;39: 229-237.
32. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayaski S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323-328.
33. van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A. ADORE Study Investigators. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis. 2008;67:1104-1110.
34. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30:1375-1384.
35. Woessner JF. Matrix metalloproteinase and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
36. Jackson CJ, Arkell J, Nguyen M. Rheumatoids synovial endo- thelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann Rheum Dis. 1998;57:158-161.
37. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future, Cytokine Growth Factor Rev. 2002;13:299-313.
38. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology. 2003;42: 83-88. (Pubitemid 36131572)
39. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003;25:3-18.
40. Frey O, Petrow PK, Gajda M, Siegmund K, Huehn J, Scheffold A, et al. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Res Ther. 2005; 7:291-301.
41. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol. 2004;4:408-414.
42. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-/? requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol. 2006;176:3321-3329.
43. Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL-2 and TGF-/? or IL-10 in the generation and function of CD4+CD25+ and CD8+ regulatory T cell subsets. J Leukocyte Biol. 2003;74:471-478.
44. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473-488.
45. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and super- oxide in inflammation and immune regulation. J Physiol Pharmacol. 2003;54:469-487.
46. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite- induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991;288: 481-487.
47. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013-12017. (Pubitemid 24368594)
48. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A. 1994;91:9407-9411.